Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: DRUG: B013+Nab-Paclitaxel
Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
Collaborators: Shanghai Pharmaceuticals Holding Co., Ltd